title: Use of magnetic resonance imaging in pharmacogenomics.
abstract: Because of the large variation in the response to psychoactive medication, many studies have attempted to uncover genetic factors that determine response. While considerable knowledge exists on the large effects of genetic polymorphisms on pharmacokinetics and plasma concentrations of drugs, effects of the concentration at the target site and pharmacodynamic effects on brain functions in disease are much less known. This article reviews the role of magnetic resonance imaging (MRI) to visualize response to medication in brain behaviour circuits in vivo in humans and assess the influence of pharmacogenetic factors. Two types of studies have been used to characterize effects of medication and genetic variation. In task-related activation studies the focus is on changes in the activity of a neural circuit associated with a specific psychological process. The second type of study investigates resting state perfusion. These studies provide an assessment of vascular changes associated with bioavailability of drugs in the brain, but may also assess changes in neural activity after binding of centrally active agents. Task-related pharmacogenetic studies of cognitive function have characterized the effects in the prefrontal cortex of genetic polymorphisms of dopamine receptors (DRD2), metabolic enzymes (COMT) and in the post-synaptic signalling cascade under the administration of dopamine agonists and antagonists. In contrast, pharmacogenetic imaging with resting state perfusion is still in its infancy. However, the quantitative nature of perfusion imaging, its non-invasive character and its repeatability might be crucial assets in visualizing the effects of medication in vivo in man during therapy.
authors.affiliation: Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany; Institute of Psychology, University of Innsbruck, Innsbruck, Austria.
authors.forename: Roberto
authors.initials: R
authors.lastname: Viviani
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Lehmann
authors.forename: Julia C
authors.initials: JC
authors.lastname: Stingl
mesh_terms: D001921:Brain / Q000098:blood supply / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D018491:Dopamine Agonists / Q000494:pharmacology; D059907:Functional Neuroimaging / Q000379:methods; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D008279:Magnetic Resonance Imaging / Q000639:trends*; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D011110:Polymorphism, Genetic; D011597:Psychomotor Performance / Q000187:drug effects*
chemical_list: D018491:Dopamine Agonists
keywords: neuroleptics; perfusion imaging; pharmacogenetic imaging